InforMing the PAthway of COPD Treatment (IMPACT) trial: fibrinogen levels predict risk of moderate or severe exacerbations

被引：0
作者：
Dave Singh
Gerard J. Criner
Mark T. Dransfield
David M. G. Halpin
MeiLan K. Han
Peter Lange
Sally Lettis
David A. Lipson
David Mannino
Neil Martin
Fernando J. Martinez
Bruce E. Miller
Robert Wise
Chang-Qing Zhu
David Lomas
机构：
[1] The University of Manchester,Centre for Respiratory Medicine and Allergy, Institute of Inflammation and Repair, Manchester Academic Health Science Centre
[2] Manchester University NHS Foundation Trust,Pulmonary and Critical Care Medicine
[3] Lewis Katz School of Medicine at Temple University,Division of Pulmonary, Allergy, and Critical Care Medicine, Lung Health Center
[4] University of Alabama at Birmingham,University of Exeter Medical School, College of Medicine and Health
[5] University of Exeter,Department of Public Health
[6] University of Michigan,Pulmonary, Allergy and Critical Care Division, Department of Medicine, Perelman School of Medicine
[7] Pulmonary & Critical Care,Institute for Lung Health
[8] University of Copenhagen,Division of Pulmonary and Critical Care Medicine
[9] Biostatistics,Division of Medicine
[10] GlaxoSmithKline,undefined
[11] Clinical Sciences,undefined
[12] GlaxoSmithKline,undefined
[13] University of Pennsylvania,undefined
[14] University of Kentucky College of Public Health,undefined
[15] Global Medical Affairs,undefined
[16] GlaxoSmithKline,undefined
[17] University of Leicester,undefined
[18] Weill Cornell Medicine,undefined
[19] Johns Hopkins University School of Medicine,undefined
[20] UCL Respiratory,undefined
[21] Rayne Building,undefined
[22] University College London,undefined
来源：
Respiratory Research | / 22卷
关键词：
Fibrinogen; COPD exacerbations; Pharmacotherapy; COPD;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 176 条
[1]  
Singh D(2019)Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019 Eur Respir J 53 1900164-1680
[2]  
Agusti A(2018)Once-daily single-inhaler triple versus dual therapy in patients with COPD N Engl J Med 378 1671-676
[3]  
Anzueto A(2013)Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease Thorax 68 670-864
[4]  
Barnes PJ(2010)Chronic obstructive pulmonary disease biomarker(s) for disease activity needed–urgently Am J Respir Crit Care Med 182 863-549
[5]  
Bourbeau J(2016)Current controversies in the pharmacological treatment of chronic obstructive pulmonary disease Am J Respir Crit Care Med 194 541-118
[6]  
Celli BR(2010)Impact of exacerbations on COPD Eur Respir Rev 19 113-1192
[7]  
Criner GJ(2011)Changes in forced expiratory volume in 1 second over time in COPD N Engl J Med 365 1184-613
[8]  
Frith P(2016)Plasma fibrinogen qualification as a drug development tool in chronic obstructive pulmonary disease. Perspective of the Chronic Obstructive Pulmonary Disease Biomarker Qualification Consortium Am J Respir Crit Care Med 193 607-1204
[9]  
Halpin DMG(2019)Chronic obstructive pulmonary disease biomarkers and their interpretation Am J Respir Crit Care Med 199 1195-34
[10]  
Han M(2015)Plasma fibrinogen as a biomarker for mortality and hospitalized exacerbations in people with COPD Chronic Obstr Pulm Dis 2 23-5268
12345678910